On August 5, Kang Fang Biotech announced that its overseas partner Summit Therapeutics, which developed the world's first PD-1/VEGF dual-antibody drug, will conduct a phase II/III international multi-center registered clinical study of evossi combined with vintuizumab compared with pabolizumab combined with EV to treat locally advanced or metastatic urothelial carcinoma on the first line. Currently, Kang Fang Biotech is responsible for promoting the Chinese research part of Harmoni-GU1, and SUMMIT is responsible for carrying out overseas research parts of Harmoni-GU1 research, including the US and Europe.
Zhitongcaijing · 2d ago
Share
Listen to the news
On August 5, Kang Fang Biotech announced that its overseas partner Summit Therapeutics, which developed the world's first PD-1/VEGF dual-antibody drug, will conduct a phase II/III international multi-center registered clinical study of evossi combined with vintuizumab compared with pabolizumab combined with EV to treat locally advanced or metastatic urothelial carcinoma on the first line. Currently, Kang Fang Biotech is responsible for promoting the Chinese research part of Harmoni-GU1, and SUMMIT is responsible for carrying out overseas research parts of Harmoni-GU1 research, including the US and Europe.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending